Seeking Alpha

GTx (GTXI) says two Phase III clinicals of Enobosarm will continue after a planned safety...

GTx (GTXI) says two Phase III clinicals of Enobosarm will continue after a planned safety review. The company is compiling an "extensive safety database" as clinical trials progress for the company's cancer-related muscle deterioration treatment which was given Fast Track designation by the FDA in January. GTXI plans to file for marketing approval in Q3. Stifel Nicolaus calls the drug a "significant value-creating event."
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector